Analysts Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20

Shares of Pharvaris (NASDAQ:PHVS) have been given an average recommendation of “Buy” by the five research firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $36.20.

Several equities analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $27.00 price target on shares of Pharvaris in a research report on Thursday, June 5th. Guggenheim assumed coverage on shares of Pharvaris in a research note on Wednesday. They set a “buy” rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald decreased their target price on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC increased its stake in Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock worth $103,429,000 after buying an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in shares of Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after acquiring an additional 216,483 shares during the period. Octagon Capital Advisors LP grew its position in shares of Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after purchasing an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP raised its stake in Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after purchasing an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after purchasing an additional 118,408 shares in the last quarter.

Pharvaris Trading Down 3.1%

PHVS opened at $16.70 on Wednesday. The company has a market cap of $873.24 million, a price-to-earnings ratio of -5.96 and a beta of -2.86. The stock has a fifty day simple moving average of $15.93 and a two-hundred day simple moving average of $16.90. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). On average, analysts predict that Pharvaris will post -2.71 EPS for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.